That is to say, the active components of YGJ that cross the BBB can restore the normal function of estrogen and insulin in the brain by acting on ERBB2, ESR1, ESR2, IGF1R, MAP2K1, and MAPK1, thereby reducing the incidence, slowing down the progression, and improving related symptoms of PD by affecting the central nervous. This evidence concerns the gene MAP2K1 and Parkinson disease.